Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BIBF 1120 maintenance after chemotherapy in relapsed ovarian cancer
2005-002427-14Phase 2Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Sep 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC) comparing BIBF 1120 maintenance with Matching placebo maintenance (2 arms). Primary endpoints: Progression-free survival rate at 9 months and Time to tumor progression. Started Sep 2005; status: completed.
02
Drugs
nintedanib
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on 2005-002427-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-002427-14.